http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102516323-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e89c206df73c7928c3fa05f87f1287de |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 |
| filingDate | 2011-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_935fd81ef48f65e9b3e6320cebb0f706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_878c39eebdc704cb31685d3e063aecb4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd312ca00c71af0ff5b16185f67e8b0b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcb35eab17689323afe7fc71d247dc1d |
| publicationDate | 2014-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102516323-B |
| titleOfInvention | Low molecular weight carrageenan oligosaccharide and preparation method and application thereof |
| abstract | The invention provides a low molecular weight carrageenan oligosaccharide. The low molecular weight carrageenan oligosaccharide is formed by alternative connections of 1,3-beta-D galactose and1,4-alpha-D galactose, and has a weight-average molecular weight of 1-3 kD and a structural formula of G4S-[A-G4S] <n->, wherein n is 1-7, and a sulfate radical content is 8-12%. The carrageenan oligosaccharide can not only oppose infection of Influenza A virus subtype H1N1 in vitro, but also substantially mitigate mice lung inflammation caused by virus infection, reduce mortality and prolong survival time. The carrageenan oligosaccharide of the invention is from sea red alga, has many advantages of wide source, low toxicity and high efficiency, can well inhibit infection of Influenza A virus in vitro and in vivo and has wide market application prospect in controlling Influenza A virus. |
| priorityDate | 2011-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 229.